Division of Vascular and Endovascular Surgery, Department of Surgery, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
BMJ Open. 2022 Apr 7;12(4):e053920. doi: 10.1136/bmjopen-2021-053920.
Overuse of cardiovascular healthcare services, defined as the provision of low-value (ineffective, harmful, cost-ineffective) tests, medications and procedures, may be common and associated with increased patient harm and health system inefficiencies and costs. We seek to systematically review the evidence for overuse of different cardiovascular healthcare services in high-income countries.
We will search MEDLINE, EMBASE and Evidence-Based Medicine Reviews from 2010 onwards. Two investigators will independently review titles and abstracts and full-text studies. We will include published English-language studies conducted in high-income countries that enrolled adults (mean/median age ≥18 years) and reported the incidence or prevalence of overuse of cardiovascular tests, medications or procedures; adjusted risk factors for overuse; or adjusted associations between overuse and outcomes (reported estimates of morbidity, mortality, costs or lengths of hospital stay). Acceptable methods of defining low-value care will include literature review and multidisciplinary iterative panel processes, healthcare services with reproducible evidence of a lack of benefit or harm, or clinical practice guideline or Choosing Wisely recommendations. Two investigators will independently extract data and evaluate study risk of bias in duplicate. We will calculate summary estimates of the incidence and prevalence of overuse of different cardiovascular healthcare services across studies unstratified and stratified by country; method of defining low-value care; the percentage of included females, different races, and those with low and high socioeconomic status or cardiovascular risk; and study risks of bias using random-effects models. We will also calculate pooled estimates of adjusted risk factors for overuse and adjusted associations between overuse and outcomes overall and stratified by country using random-effects models. We will use the Grading of Recommendations, Assessment, Development and Evaluation to determine certainty in estimates.
No ethics approval is required for this study as it deals with published data. Results will be presented at meetings and published in a peer-reviewed journal.
CRD42021257490.
心血管保健服务的过度使用,定义为提供低价值(无效、有害、无成本效益)的检查、药物和程序,可能很常见,并与增加的患者伤害以及卫生系统效率低下和成本增加有关。我们旨在系统地审查高收入国家不同心血管保健服务过度使用的证据。
我们将搜索 2010 年以来的 MEDLINE、EMBASE 和循证医学评论。两名调查员将独立审查标题和摘要以及全文研究。我们将包括发表在高收入国家的、纳入成年人(平均/中位数年龄≥18 岁)并报告心血管检查、药物或程序过度使用的发生率或流行率;过度使用的调整风险因素;或过度使用与结果(报告发病率、死亡率、成本或住院时间的估计值)之间的调整关联的已发表的英文研究。可接受的低价值护理定义方法包括文献综述和多学科迭代小组流程、具有可重复缺乏益处或危害证据的医疗保健服务,或临床实践指南或明智选择建议。两名调查员将独立重复提取数据并评估研究的偏倚风险。我们将计算不同心血管保健服务过度使用的发生率和流行率的汇总估计值,这些估计值未经分层和按国家分层;低价值护理的定义方法;纳入的女性、不同种族以及低和高社会经济地位或心血管风险的比例;以及使用随机效应模型的研究偏倚风险。我们还将使用随机效应模型计算过度使用的调整风险因素和过度使用与结果之间的调整关联的汇总估计值,这些估计值按国家分层。我们将使用推荐评估、制定与评估分级法(Grading of Recommendations, Assessment, Development and Evaluation)来确定估计值的确定性。
由于本研究涉及已发表的数据,因此不需要伦理批准。结果将在会议上公布,并在同行评议的期刊上发表。
PROSPERO 注册号:CRD42021257490。